Category: ACN Newswire

香港, 2026年2月3日 - (亞太商訊 via SeaPRwire.com) - 全球最大釣魚裝備製造商樂欣戶外（股票代碼2720.HK）正式啟動招股，擬全球發售2820.5萬股，其中10%為香港公開發售。每股定價12.25港元。預計2月10日在聯交所掛牌上市。此次IPO擬集資約3.45億港元，中金公司擔任獨家保薦人。市場地位穩固，龍頭份額持續提升根據弗若斯特沙利文的權威數據，全球釣魚用具市場規模預計將於2029年達到1941億元，其中全球釣魚裝備市場展現出更快的增長勢頭，2025年至2029年的複合年增長率預計為9.5%，明顯高於行業整體。樂欣戶外作為全球最大的釣魚裝備製造商，市場份額為23.1%，同時在前五大廠商中佔據絕對主導地位。樂欣戶外亦是中國最大的釣魚裝備製造商，市場份額由2022年的23.4%穩步增長至2024年的28.4%，展現出持續增長潛力。中國釣魚裝備製造業也更為集中，按2024年收入計前五大釣魚裝備製造商所佔市場份額為39.4%。業績穩健增長，產品線覆蓋全面在財務數據層面，樂欣戶外營收保持高速穩健增長，2024年營收達5.73億元，較2023年實現23.8%的同比增長；2025年前八個月收入已達4.60億元，接近2024年全年的80%，顯示增長節奏穩健。公司2025年前八個月實現經營利潤7769.5萬元，接近2022年歷史較好水平，為公司戰略擴張提供了堅實的資本基礎。2025年前八個月淨利潤達5624.1萬元，淨利潤率維持在12.2%的健康水平，為公司戰略擴張提供了堅實的資本基礎。其中品牌業務增長迅猛，自有品牌Solar 2024年銷售額較2018年增長近三倍，儘管目前OBM業務佔比並不是很髙，但增長潛力巨大。同時，公司TO B業務持續發力，合作超過5年的客戶達84家，客戶黏性強勁，形成「TO B穩健托底+TO C突破增長」的雙增長格局，為長期資本回報提供穩定支撐。在產品矩陣層面，樂欣戶外為不同釣魚場景創造出了全面的產品解決方案。截至2025年8月31日的產品組合涵蓋10,000多個SKU，可適配釣魚人在不同地區及環境的需求，包括鯉魚釣、比賽釣、路亞釣、飛釣及冰釣等。市場前景廣闊，加碼品牌與未來 從全球格局來看，釣魚裝備市場正迎來結構性增長機遇。專業機構研究顯示，2025至2029年，全球釣魚裝備市場預計將以年均約9.5%的複合增速擴張，高於戶外行業整體水平，市場總規模有望邁向2000億元。我國垂釣裝備行業已邁入藍海發展階段，行業紅利為樂欣戶外的轉型提供了廣闊空間。機構數據顯示，2020-2024年，我國垂釣裝備行業市場規模年均複合增長率達18.92%，顯著高於全球同期水平，全球市場佔比持續提升，市場需求正從基礎功能滿足向專業化、場景化及個性化升級。此次IPO募資是樂欣戶外發展歷程中的重要里程碑，亦是其在資本層面提升核心競爭力、拓展戰略布局的關鍵舉措。伴隨全球休閒釣魚生活方式的熱潮，消費者對高品質釣魚裝備的需求持續攀升，新興市場的增速尤為顯著。作為全球規模最大的釣魚裝備製造商，樂欣戶外可依託自身產能與產品優勢，充分承接這一藍海市場的需求紅利，為品牌升級與市場拓展築牢基礎，迎來全新的發展機遇。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年2月3日 - (亞太商訊 via SeaPRwire.com) - 近日，由上海實業（集團）有限公司（以下簡稱“上實集團”）與Azzurra Capital聯合發起設立的亞洲環境科技合夥企業（Asia Environmental Technology Fund，簡稱“AETF”），已成功完成首關。AETF同步密集召開系列重要會議、深化多方合作對接，穩步推進落地運營與儲備項目佈局。作為上實集團與Azzurra Capital聯手打造的專業綠色投資平台，AETF擬定目標規模為5億美元。AETF將立足香港、面向全球，錨定綠色發展時代機遇，滙聚亞歐及中東優質資本支持，致力於成為跨境環境科技投資領域的標杆力量。依託「歐洲技術引進+亞洲企業出海」的雙向跨境賦能模式，AETF將國際私募股權的專業投研能力與上實集團深厚的產業資源深度融合，緊扣全球ESG主題尤其是環境科技投資目標，充分借助亞洲工業基礎與政策紅利，精選具備高增長潛力的投資標的。通過雙向賦能策略，既加速歐洲前沿環境技術在亞洲的場景落地，也助力亞洲綠色龍頭企業邁向全球，兼顧成熟項目的穩健回報與早期科技項目的成長潛力，助力亞洲穩步邁向「碳達峰、碳中和」綠色未來。AETF將重點涵蓋可再生能源產業鏈、能源轉化和儲能技術、賦能綠色低碳發展的數智化技術（AI、IoT及智能製造）、循環經濟與資源再生、可持續農業與未來食品體系、氣候科技（CCUS）及環境監測解決方案、具備全球出口競爭力的綠色消費品與可持續生活方式等領域。1月27日，AETF的GP公司召開首屆董事會，凝聚合作共識、明晰推進路徑、建立合規體系、儲備重點項目、細化落實舉措。在董事會召開期間，AETF董事和高管團隊圍繞落地運營、投資策略優化、多方合作拓展等召開了一系列專題會議，並同步拜訪了香港多家知名機構，圍繞環境健康領域潛在投資機遇、合作模式創新、跨境金融合規建設、項目協同聯動、優質資源分享等議題深入交流討論，為AETF精準對接香港本地優質資源、拓寬跨境合作版圖築牢根基。上實集團與Azzurra Capital將憑藉各自獨特優勢，構建起優勢互補、協同發展的良好合作格局。上實集團自1981年在香港成立以來，聚焦生命健康與環境健康兩大核心賽道，在產業整合、項目運營、本地資源對接等方面積累了深厚底蘊與豐富經驗。Azzurra Capital作為擁有成熟跨境基金管理經驗的知名投資機構，資產管理規模近9億美元，在歐洲、中東等地擁有廣泛的優質資源與優秀的投資業績，深耕綠色科技與可持續發展領域，專業能力獲行業認可。雙方攜手發起設立AETF，既是響應全球低碳轉型號召、踐行綠色發展理念的重要舉措，也是深化跨境投資合作、支援滬港協同發展，賦能亞洲環境科技產業高質量發展的具體實踐，更是雙方實現優勢互補、合作共贏的戰略抉擇。香港當前正在全力發展創科、綠色金融等新引擎，通過扮演更積極的「超級聯繫人」和「超級增值人」角色，在服務國家大局中實現自身的高質量發展。作為上實集團在港開展金融投資業務的平台，上實資本（香港）本次與Azzurra Capital合作攜手發起設立AETF，是上實資本（香港）緊抓當前香港發展機遇，服務在港發展，充分激發「香港所長」與「上海所能」的互補勢能，系統推動兩地創新鏈、產業鏈、資金鏈與人才鏈的深度融合的具體實踐，將為加快構建開放融合、連結全球的創新生態系統，為滬港國際科技創新中心建設提供支撐。上實集團首席金融投資官谷峰先生表示，此次與Azzurra Capital的合作，是上實集團將深厚產業資源與全球資本及頂尖投資管理經驗深度融合的重要戰略舉措。期待通過AETF這一平台，不僅投資技術，更致力於培育產業。我們將積極開放自身的應用場景與生態系統，為優秀的綠色科技企業提供從驗證到規模化發展的全方位支援，共同推動亞太區域的綠色轉型與高質量發展。Azzurra Capital創始合夥人Stefano Eugenio Marsaglia指出，亞洲作為全球低碳轉型的核心陣地，擁有巨大的投資潛力與廣闊的發展空間，綠色發展已成為不可逆轉的時代潮流。AETF的成功設立，搭建起了連接歐洲、中東與亞洲綠色投資市場的重要橋樑，未來將充分發揮雙方專業優勢，推動先進技術、優質資本與廣闊市場的跨境流動，全力打造亞洲環境科技投資領域的標杆，為全球低碳轉型貢獻力量。風勁潮湧正當時，揚帆奮進啟新程。AETF將以此次首關為重要契機，加速推進後續擴募進程，聚焦核心投資領域精準發力、推進優質項目落地見效，持續深化與各方機構的合作對接，積極開展品牌建設與行業交流。AETF將始終以「歐洲技術引進+亞洲企業出海」雙向策略為核心，持續作為雙方跨境綠色合作的核心載體，在各類行業峰會中傳遞合作價值、連結優質資源。AETF將以資本為紐帶、以創新為動力，賦能亞洲環境科技產業高質量發展，推動ESG投資理念深度落地，為全球低碳轉型注入持久動能、貢獻堅實力量。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

MIAMI, FL, Feb 2, 2026 - (ACN Newswire via SeaPRwire.com) - Digi Power X Inc. ("Digipower X" or the "Company") (Nasdaq:DGXX)(TSXV:DGX), a vertically integrated AI infrastructure company focused on the deployment of Tier-3 modular data centers powered by owned and controlled energy assets, today announced that Hans Vestberg, former Chairman and Chief Executive Officer of Verizon Communications, has joined the Company as a senior advisor serving on its Advisory Board to support the Company's expansion strategy.Mr. Vestberg brings more than three decades of global leadership in mission-critical infrastructure, telecommunications networks, and large-scale capital deployment. He is widely recognized for leading Verizon's first commercial 5G deployment in 2018 and for advancing nationwide fiber, mobile edge computing, and next-generation network architectures.Prior to Verizon, Mr. Vestberg spent nearly three decades at Ericsson, including almost seven years as its Chief Executive Officer, where he helped build and operate global infrastructure facilitating approximately 35% of worldwide mobile traffic.Mr. Vestberg's appointment comes at a time when AI adoption is increasingly constrained, not by software or silicon, but by power availability, cooling capacity, and deployment speed. Digipower X is working on addressing this challenge through the deployment of the AI-Ready Modular Solution (ARMS) platform, designed to deliver Tier-3 modular AI data centers within approximately 180 days, supported by a vertically integrated power strategy and a growing portfolio of large-scale energy assets."Hans Vestberg built and scaled the physical infrastructure that helped enable the fiber, mobile, and 5G revolutions," said Michel Amar, Chairman and Chief Executive Officer of Digipower X. "He understands what most of the market overlooks: AI's bottleneck isn't algorithms or chips, it's power, cooling, and deployment speed. Hans knows how to execute infrastructure transformation at a national and global scale, and we expect his guidance will be invaluable as we expand our modular AI data center footprint.""I've spent over 30 years building the networks that move data," said Mr. Vestberg. "The next decade is about building the infrastructure that processes it. Digipower X is more than just a data center company. It controls its power, is developing the ability to deploy Tier-3 infrastructure in the near term, and is building a modular platform to address the exact constraints holding back large-scale AI deployment. Its focus on power availability and deployment speed first, real estate second, is exactly the right approach."Infrastructure Experience Aligned with AI ScaleDuring his tenure at Ericsson (2010-2016), Mr. Vestberg led more than 115,000 employees worldwide and positioned the company at the forefront of next-generation wireless technologies. At Verizon (2018-2025), he reshaped the organization around a network-first strategy, oversaw major investments in spectrum and fiber, and advanced distributed edge-compute capabilities to enable data-intensive and latency-sensitive applications.Mr. Vestberg insightfully noted at Davos 2024 that "one of the most important infrastructures of this century is digital infrastructure," and that AI workloads will increasingly migrate from centralized hyperscale facilities toward distributed locations supporting real-time inference and enterprise demand.Mr. Vestberg currently serves as a board member of BlackRock and Verizon.Addressing the Power and Deployment Constraint in AI InfrastructureDigipower X operates a combined-cycle power plant and three additional operating sites, with more than 200 megawatts of power currently online. The Company has secured development capacity to support AI infrastructure expansion over the next three years, with the ability to develop up to an additional 1.5 gigawatts of power capacity, including at major sites in North Carolina and West Virginia.In West Virginia, Digipower X has entered into a letter of intent relating to a 1.3-gigawatt power plant, which is being evaluated as a long-term site for AI data center and advanced computing infrastructure deployment."Hans recognizes that national AI competitiveness depends on solving power availability and deployment speed," said Gerard Rotonda, Board Member of Digipower X and former CFO of Deutsche Bank Wealth & Asset Management Americas. "His experience aligns directly with Digipower X's mission to deliver infrastructure at the scale and speed this market now requires."Vestberg's Strategic FocusIn his advisory role, Mr. Vestberg will work closely with Digipower X's executive team on:AI infrastructure deployment strategy and scaling frameworks;Distributed and edge-compute architectures for inference-driven workloads;Strategic partnerships with hyperscalers, enterprises, and infrastructure stakeholders;Power optimization and energy-efficient data center design;Tier-3 redundancy and mission-critical reliability standards; andInternational expansion strategy and site prioritization.About Digipower XDigipower X is an innovative energy infrastructure company that develops Tier III-certified modular AI data centers and drives the expansion of sustainable energy assets.For further information, please contact:Michel Amar, Chief Executive OfficerDigipower X Inc.www.digipowerx.comInvestor RelationsT: 888-474-9222Email: IR@digihostpower.comCautionary StatementTrading in the securities of the Company should be considered highly speculative. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.Forward-Looking StatementsExcept for the statements of historical fact, this news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking information") that are based on expectations, estimates and projections as at the date of this news release and are covered by safe harbors under Canadian and United States securities laws. Forward-looking information in this news release includes information about the Company's expectations concerning the potential contributions by our new advisor to the Company's strategic efforts, the potential further improvements to profitability and efficiency across the Company's operations, including, as a result of the Company's expansion efforts, potential for the Company's long-term growth and clean energy strategy, and the business goals and objectives of the Company. Factors that could cause actual results to differ materially from those described in such forward-looking information include, but are not limited to: delivery of equipment and implementation of systems may not occur on the timelines anticipated by the Company or at all; future capital needs and uncertainty of additional financing; share dilution resulting from equity issuances; risks relating to the strategy of maintaining and increasing Bitcoin holdings and the impact of depreciating Bitcoin prices on working capital; statements regarding the timing, scale and expansion of AI and high-performance computing infrastructure; changes in demand for AI and high-performance computing; future data center capacity may not be realized at the level anticipated by the Company, or at all; development of additional facilities and installation of infrastructure to expand operations may not be completed on the timelines anticipated by the Company, or at all; ability to access additional power from the local power grid; the Company may not be able to profitably liquidate its current digital currency inventory, or at all; a decline in digital currency prices may have a significant negative impact on the Company's operations; the volatility of digital currency prices; and other related risks as more fully set out in the Annual Information Form of the Company and other documents disclosed under the Company's filings at www.sedarplus.ca and www.SEC.gov/EDGAR. The forward-looking information in this news release reflects the current expectations, assumptions and/or beliefs of the Company based on information currently available to the Company. In connection with the forward-looking information contained in this news release, the Company has made assumptions about, among other things, profitable use of the Company's assets going forward; the demand for data center capacity for AI and high-performance computing; and there will be no regulation or law that will prevent the Company from operating its business. The Company has also assumed that no significant events occur outside of the Company's normal course of business. Although the Company believes that the assumptions inherent in the forward-looking information are reasonable, forward-looking information is not a guarantee of future performance and accordingly undue reliance should not be put on such information due to the inherent uncertainties therein. The Company undertakes no obligation to revise or update any forward-looking information other than as required by applicable law.SOURCE: Digi Power X Inc. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

NEEDHAM, MA, Feb 2, 2026 - (ACN Newswire via SeaPRwire.com) - Bioxytran, Inc. (OTCQB: BIXT) (“Bioxytran” or the “Company”), a clinical-stage biotechnology company developing platform technologies spanning glycovirology, hypoxia, and degenerative diseases, announced the execution of a Sponsored Research Agreement with the University of Minnesota to support advanced biochemical research aimed at improving the understanding and development of novel polysaccharide and oligosaccharide interactions with biologically relevant targets.Under the agreement, research will be conducted at the University of Minnesota under the direction of Dr. Kevin Mayo, a recognized expert in biomolecular structure and nuclear magnetic resonance spectroscopy The collaboration is designed to further characterize carbohydrate-binding interactions that may play a role in future therapeutic and diagnostic applications.“This collaboration with the University of Minnesota represents an important step in strengthening the scientific foundation behind our carbohydrate-based technology platform,” said David Platt, CEO of Bioxytran. “By leveraging the University’s deep expertise in structural biology and advanced nuclear magnetic resonance spectroscopy, we aim to generate high-quality data that supports the continued evolution of our research and development pipeline.”Research FocusThe sponsored research program will explore how specific polysaccharides and related carbohydrate structures interact with target molecules relevant to biological systems. Using state-of-the-art nuclear magnetic resonance methodologies, the research team will analyze binding interactions, structural conformations, and affinity characteristics of select carbohydrate compounds. The work is expected to build on Bioxytran’s existing research into carbohydrate-based materials and their potential applications across biomedical and life-science domains. Findings from the study may help guide future development strategies and inform additional preclinical research initiatives.Academic–Industry CollaborationThe agreement reflects a shared commitment to advancing scientific knowledge through collaboration between academia and industry. The University of Minnesota will carry out the research in accordance with its established academic standards, ensuring scientific rigor, transparency, and adherence to institutional research policies.This type of partnership exemplifies how academic research institutions and innovative companies can work together to address complex scientific questions,” said Dr. Kevin Mayo, Principal Investigator and Professor at the University of Minnesota. “Our goal is to apply advanced analytical tools to generate insights that are both scientifically meaningful and relevant to real-world applications.”Timeline and StructureThe research term is expected to run through early 2027, with defined milestones, periodic progress reviews, and structured reporting. Bioxytran will provide funding to support research personnel, nuclear magnetic resonance facility access, and associated laboratory resources required to execute the program. In accordance with standard sponsored research practices, the University of Minnesota will retain ownership of any intellectual property generated through the research, while Bioxytran will receive broad rights to use the resulting research data for internal research and development purposes.Strategic SignificanceFor Bioxytran, the collaboration supports a broader strategy focused on strengthening its scientific validation, expanding academic partnerships, and advancing next-generation carbohydrate technologies. The company believes that well-characterized molecular interactions are a critical step toward unlocking new therapeutic pathways and accelerating innovation.The University of Minnesota continues to be recognized globally for its leadership in biomedical research and technology transfer, making it an ideal partner for companies seeking to bridge fundamental science and commercial development.About the University of MinnesotaThe University of Minnesota is one of the nation’s leading public research universities, known for its commitment to discovery, innovation, and the translation of research into real-world impact. Through industry partnerships and sponsored research programs, the University fosters collaboration that advances science and benefits society.About Bioxytran, Inc.Bioxytran is a clinical-stage pharmaceutical company developing platform technologies in glycovirology, hypoxia and degenerative diseases using carbohydrate drug design, including programs that leverage galectin inhibition and programs that aim to address hypoxic conditions and tissue oxygenation. Bioxytran’s common stock trades on the OTCQB under the symbol BIXT.Company Contact:Bioxytran, Inc.75 Second Avenue, Needham, MA 02494Phone: 617‑454‑1199Email: info@Bioxytraninc.comWeb: www.Bioxytraninc.comForward-Looking StatementsThis press release contains forward-looking statements, including statements regarding anticipated regulatory interactions, future clinical trials, trial designs, timing of data submission and publication, and potential therapeutic and commercial opportunities. Forward-looking statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially. Readers are urged to review the Company’s risk factors disclosed in its reports filed with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10‑K for the year ended December 31, 2024. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

深圳, 2026年1月30日 - (亞太商訊 via SeaPRwire.com) - 康哲藥業控股有限公司 （「康哲藥業」）欣然宣佈，旗下德鎂醫藥有限公司（「德鎂醫藥」，專業聚焦皮膚健康的創新型醫藥企業，正申請於香港聯合交易所有限公司主板獨立上市，詳見康哲藥業日期為2025年4月22日發佈的公告）已於2026年1月30日獲得中國國家藥品監督管理局（NMPA）批准磷酸蘆可替尼乳膏（白癜風適應症）（「產品」）新藥上市許可申請（NDA）。產品用於治療12歲及以上兒童和成人患者伴面部受累的非節段型白癜風，是中國批准的首款且唯一用於白癜風治療的靶向藥，滿足巨大未被滿足的臨床需求。磷酸蘆可替尼乳膏是經美國食品和藥物管理局（FDA）及歐洲藥品管理局（EMA）批准的首款也是唯一一款用於非節段型白癜風複色的藥物[1,2]，在產品正式獲得NDA批准之前，康哲藥業受益於國家賦予海南自由貿易港及樂城先行區（「樂城先行區」）「先行先試」政策、「港澳藥械通」政策、北京市及天津自貿試驗區的臨床急需進口藥品政策，已啟動磷酸蘆可替尼乳膏的試點應用。目前博鰲超級醫院已為超7,000名非節段型白癜風患者開具磷酸蘆可替尼乳膏處方，且廣州、深圳、東莞、佛山、中山、珠海、江門、惠州、北京及天津共二十餘家醫院已提供該藥品處方服務，體現了其臨床價值。產品在境外臨床研究與中國真實世界研究中均展現出積極結果：其在境外開展的兩項相同設計的III期雙盲、隨機、安慰劑對照研究（TRuE-V1和TRuE-V2）中，產品治療24周後達到主要療效指標面部白癜風面積評分指數改善至少75%（F-VASI 75）的患者比例均為29.9%，顯著高於安慰劑組的7.5%和12.9%，持續使用至52周，複色效果持續[3]。根據樂城先行區藥品真實世界數據應用試點項目有關規定，磷酸蘆可替尼乳膏在中國開展真實世界研究，療效積極，與境外關鍵臨床研究結果一致。境內外臨床研究中所有的次要療效指標均顯示出與主要療效指標一致的獲益趨勢，且白癜風治療效果隨療程延長持續改善。同時，根據樂城先行區安全性監測數據，未發現新的安全性事件，未發生導致停藥或退出的不良事件（AE），未發生研究藥物相關的嚴重不良事件（SAE）。 此次產品白癜風適應症獲批，將為國內千萬白癜風患者帶來治療新希望，滿足市場迫切的臨床需求。同時，產品將進一步豐富德鎂醫藥在皮膚治療領域的產品矩陣，並有望與現有處於商業化階段的創新藥益路取（替瑞奇珠單抗注射液）、獨家藥喜遼妥（多磺酸粘多糖乳膏），以及系列在研創新藥和皮膚學級護膚品等在專家網絡與市場資源等方面產生協同，提升德鎂醫藥在皮膚健康領域的地位。此外，康哲藥業於中國開展的磷酸蘆可替尼乳膏治療輕中度特應性皮炎患者的III期臨床試驗，已取得陽性結果。截至目前，康哲藥業正在中國積極推進磷酸蘆可替尼乳膏治療特應性皮炎的新藥上市申請，如若獲批上市，將為中國廣大特應性皮炎患者群體提供新的治療選擇。關於白癜風適應症白癜風是一種慢性自身免疫性疾病，其特徵是皮膚色素脫失，其發病原因為產生色素的細胞即黑素細胞的缺失。據估算，中國約有1030萬人患有白癜風，其中約820萬人患有非節段型白癜風[4]。現有療法，如外用糖皮質激素（TCS）及外用鈣調神經磷酸酶抑制劑（TCIs）存在臨床缺陷，長期用藥有不良反應或療效有限。磷酸蘆可替尼乳膏NDA獲批，成功填補了白癜風靶向藥物治療的空白，具有重大標誌性意義。關於磷酸蘆可替尼乳膏的更多資訊磷酸蘆可替尼乳膏（Opzelura®）是Incyte開發的選擇性JAK1/JAK2抑制劑蘆可替尼製成的一種創新型乳膏，在美國獲批用於局部治療成人及12歲及以上患者的非節段型白癜風，及2歲及以上非免疫力功能低下患者的輕度至中度特應性皮炎的局部短期和非連續性慢性治療。在歐洲，磷酸蘆可替尼乳膏被批准用於治療成年及12歲及以上青少年面部受累的非節段型白癜風。康哲藥業於2022年12月2日，通過德鎂醫藥的附屬公司與Incyte就磷酸蘆可替尼乳膏訂立合作和許可協議（「許可協議」），獲得在中國大陸、香港特別行政區、澳門特別行政區、台灣地區及東南亞十一國（「區域」）研發、注冊及商業化產品的獨家許可權利，以及在區域內生產產品的非獨家許可權利。德鎂醫藥的附屬公司已將磷酸蘆可替尼乳膏除中國大陸外的其他區域的相關權利再許可予康哲藥業（不包括德鎂醫藥及其附屬公司）。Incyte擁有磷酸蘆可替尼乳膏全球開發和商業化權利，在美國及歐洲以Opzelura®的名稱銷售。Opzelura®和Opzelura®標識是Incyte的註冊商標。關於康哲藥業康哲藥業是一家鏈接醫藥創新與商業化，把控產品全生命週期管理的開放式平臺型企業，致力於提供有競爭力的產品和服務，滿足尚未滿足的醫療需求。康哲藥業專注於全球首創（FIC）及同類最優（BIC）的創新產品，並高效推進創新產品臨床研究開發和商業化進程，賦能科研成果向診療實踐的持續轉化，造福患者。康哲藥業聚焦專科領域，擁有被驗證的商業化能力，廣泛的渠道覆蓋和多疾病領域專家資源，核心在售產品已獲領先的學術與市場地位。康哲藥業圍繞優勢專科領域不斷縱深發展，以鞏固心腦血管/消化/眼科/皮膚健康業務競爭力，帶來專科規模效率，其中皮膚健康業務（德鎂醫藥）已成為其細分領域的龍頭企業，並擬於聯交所獨立上市。同時，康哲藥業持續推動研產銷全產業鏈在東南亞及中東區域運營發展，以獲取新興市場的增量，助力集團實現高質量可持續發展。參考文獻/資料1.FDA批准資訊可在Incyte官網查詢，網址：https://investor.incyte.com/news-releases/news-release-details/incyte-announces-us-fda-approval-opzeluratm-ruxolitinib-cream2.EMA批准資訊可在Incyte官網查詢，網址：https://investor.incyte.com/news-releases/news-release-details/incyte-announces-european-commission-approval-opzelurar3.相關臨床研究資訊可在Opzelura®官網查詢，網址：https://www.opzelura.com/opzelura-prescribing-information4.數據來自灼識諮詢報告康哲藥業免責與前瞻性聲明本新聞無意向您做任何產品的推廣，非廣告用途。本新聞不對任何藥品和-醫療器械和/或適應症作推薦。若您想瞭解具體疾病診療資訊，請遵從醫生或其他醫療衛生專業人士的意見或指導。醫療衛生專業人士作出的任何與治療有關的決定應根據患者的具體情況並遵照藥品說明書。由康哲藥業編制的此新聞不構成購買或認購任何證券的任何要約或邀請，不形成任何合約或任何其他約束性承諾的依據或加以依賴。本新聞由康哲藥業根據其認為可靠之資料及數據編制，但康哲藥業並無進行任何說明或保證、明述或暗示，或其他表述，對本新聞內容的真實性、準確性、完整性、公平性及合理性不應加以依賴。本新聞中討論的若干事宜可能包含涉及康哲藥業的市場機會及業務前景的陳述，該等陳述分別或統稱為前瞻性聲明。該等前瞻性聲明並非對未來表現的保證，存在已知及未知的風險、不明朗性及難以預知的假設。康哲藥業並不採納本新聞包含的第三方所做的任何前瞻性聲明及預測，康哲藥業對該等第三方聲明及預測不承擔責任。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

TSUKUBA, Japan, Feb 2, 2026 - (ACN Newswire via SeaPRwire.com) - Modern industry relies heavily on catalysts, which are substances that speed up chemical reactions. They’re vital in everything from manufacturing household chemicals to generating clean energy or recycling waste. However, designing new catalysts is challenging because their performance is affected by many interacting factors.A new tool uses a catalyst gene profiling, where catalysts are represented as symbolic sequences, making it easier for scientists to interpret data and design catalysts without a need for programming skills.A new tool developed by researchers at Hokkaido University, published in Science and Technology of Advanced Materials: Methods, will simplify the process by providing researchers with a way to easily view and explore data about catalysts, enabling them to identify patterns and relationships in catalyst datasets without needing advanced programming or computational skills.The tool takes advantage of an approach known as catalyst gene profiling, where catalysts are represented as symbolic sequences. This makes it easier for scientists to interpret the data and apply sequence-based analysis methods to design and improve catalysts. The tool itself is a web-based graphical interface that offers an intuitive and interactive way to investigate these catalyst profiles.“The system enables researchers to explore complex catalyst datasets, identify global trends, and recognize local features—all without requiring advanced programming skills,” explains Professor Keisuke Takahashi, who led the study. “By visualizing both the relationships among catalysts and the underlying gene-based features, the platform makes catalyst design more interpretable, accessible, and efficient, bridging the gap between data-driven analysis and practical experimental insight.”Users can view catalysts clustered together based on how similar their features are or how similar their sequences are. The tool also includes a heat map that offers insights into how the catalyst gene sequences are calculated. The different visualizations can be viewed side by side and are synchronized so they all update simultaneously when a user zooms in or selects a group of catalysts.The team plans to extend the tool to work with other material science datasets so it can be used more broadly in the field. They’re also working to include a predictive component. Integrating modeling and editing strategies would mean researchers could use the tool not only to explore existing catalysts but also to investigate new ideas for high-performance materials. In addition, they want to improve the tool’s collaborative features so that several researchers can work together to explore and annotate datasets, enabling a community-oriented, data-driven approach to material design and discovery.“Our goal is to make advanced materials research more intuitive, approachable, and impactful,” says Takahashi.Further informationKeisuke TakahashiHokkaido University keisuke.takahashi@sci.hokudai.ac.jpPaper: https://doi.org/10.1080/27660400.2025.2600689 About Science and Technology of Advanced Materials: Methods (STAM-M)STAM Methods is an open access sister journal of Science and Technology of Advanced Materials (STAM), and focuses on emergent methods and tools for improving and/or accelerating materials developments, such as methodology, apparatus, instrumentation, modeling, high-through put data collection, materials/process informatics, databases, and programming. https://www.tandfonline.com/STAM-MDr Kazuya SaitoSTAM Methods Publishing Director SAITO.Kazuya@nims.go.jpPress release distributed by Asia Research News for Science and Technology of Advanced Materials. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

NEW YORK, Feb 1, 2026 - (ACN Newswire via SeaPRwire.com) - TCG.Zone (The Collectors Grid), a key player in the global collectibles infrastructure and ecosystem, has officially unveiled its strategic shift toward prioritizing investments in high-value, rare collectible assets. This strategic realignment underscores the company’s commitment to tapping into the long-term value and cultural significance of elite collectibles, with the recent participation in a high-profile international auction serving as a pivotal first step in this new direction.Recently, the world's only Pokémon card graded PSA 10 - Pikachu Illustrator - once again became a focal point of global attention across the collectibles and cultural landscape. As a long-term contributor to TCG infrastructure and the broader collectibles ecosystem, The Collectors Grid(TCG.Zone) participated in and witnessed this historically significant moment.Recognized as one of the most iconic works in Pokémon card history, Pikachu Illustrator is distinguished not only by its extreme rarity, but also by its symbolic representation of Pokémon culture, artistic value, and generational memory.The Legendary Status of the World's Only PSA 10According to publicly available information, the world's only PSA 10 "Pikachu Illustrator" card is currently owned by Logan Paul. The card was involved in a high-profile transaction in 2022, valued at nearly USD 5.3 million, marking a defining milestone in the history of Pokémon card collecting.The Industry Significance of Goldin AuctionsAlthough Logan Paul's acquisition of the card did not take place through Goldin, the Goldin auction platform has continued to play an important role in the card's contemporary circulation and visibility. As one of the world's most influential high-end collectibles auction platforms, Goldin's auction framework and the attention it generates brought renewed global focus to this legendary card, further positioning Pokémon cards within the broader mainstream collectibles market.Netflix Documentary Captures a Cultural MomentAmid the phenomenon-level attention generated by this card on the Goldin platform, Netflix documented the full auction process and produced a dedicated documentary. Approached from a cultural and historical perspective, the documentary highlights the unique position of Pikachu Illustrator within the modern collectibles ecosystem, elevating it beyond price alone and framing it as a lasting cultural reference.Global Participation and TCG.Zone's InvolvementThe discussions and auction activity surrounding Pikachu Illustrator attracted participation from top collectors, institutions, and professional teams from around the world. TCG.Zone was among the active participants in the bidding process. During the auction, TCG.Zone submitted a bid of USD 5,000,000. Although the bid was ultimately surpassed by a higher offer, TCG.Zone remained deeply engaged throughout the process and witnessed this pivotal moment firsthand.Continuing to Follow the Card's Future TrajectoryIn post-auction interviews, TCG.Zone stated that this participation does not mark an endpoint. The team will continue to closely monitor the movement and future trajectory of the world's only PSA 10 Pikachu Illustrator, and does not rule out participating again should the right opportunity arise. This event represents more than an auction. It stands as a collective reflection on rarity, cultural identity, and long-term value.The story of Pikachu Illustrator continues to unfold,and remains an enduring chapter in the global history of Pokémon card collecting.About TCGThe Collectors Grid is an on-chain infrastructure designed to formalize collectibles as a structured asset class. By integrating provenance, ownership, pricing, and settlement at the protocol level, it addresses long-standing inefficiencies in the global collectibles market. The platform enables institutional-grade transparency while preserving the unique characteristics of collectible assets. Positioned as a settlement layer rather than a marketplace, The Collectors Grid provides the foundational rails for liquidity, valuation, and long-term capital participation in cards, IP, and high-value collectibles.Social LinksTwitter: https://x.com/tcgzoneofficialInstagram: https://www.instagram.com/tcgzoneofficial/Telegram: https://t.me/tcgzoneofficialMedia ContactBrand : The Collectors Grid (tcg.zone)Contact: AnnieWebsite: https://www.tcg.zone Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

MOSCOW, Jan 31, 2026 - (ACN Newswire via SeaPRwire.com) - Expert Dialogues were held for the first time within the Open Dialogue framework at the Russia National Centre in Moscow on 30 January. The forum focused on five major megatrends shaping global economic, technological, and social development, bringing together international experts to explore how these forces will influence societies and industries in the decades ahead.Organized by the Russia National Centre in partnership with the Centre for Cross-Industry Expertise "The Third Rome" and supported by the Presidential Executive Office, the forum brought together experts from around the world to discuss economic, technological, and social transformations.Maksim Oreshkin, Deputy Head of the Russian Executive Administration for Global Trends, presented five key megatrends that, he said, are already shaping global development and will continue to influence the world in the coming decades."By 2026, Open Dialogue has become an international platform uniting experts from across the world to discuss the future of the planet, the global economy, and society," Oreshkin said. "Understanding these processes is essential for preparing for change and leveraging it in the interests of nations and, above all, people. Today, I will focus on five key megatrends — while not treating artificial intelligence as a separate trend, because it has already become an integral part of our lives."1. A New Global Economic Paradigm: Globalisation 2.0A shift from traditional globalisation to a more decentralised system was described. BRICS+ countries now play a growing role in the global economy, technological development, and demographic trends, while the Global South is increasingly engaging in direct trade and national-currency settlements."Globalisation hasn't ended; it has changed," Oreshkin said. "Sovereignty — at state, social, and economic levels — is now the key to competitiveness. Only countries that preserve all three levels can lead in a multipolar world."China, the USA, India, and Russia are identified as major global powers, while highlighting emerging growth centres such as Indonesia and "connector countries" like the United Arab Emirates. Digital platforms and decentralised networks are also becoming independent participants in the world economy.2. Platformisation and Institutional AutomationThe second megatrend highlights the rise of platforms and automation across all sectors. Platforms and algorithms are increasingly shaping decision-making in healthcare, education, finance, trade, and beyond."Platform solutions enhance efficiency and reduce transaction costs through self-adjusting algorithms," Oreshkin said. "Countries without technological sovereignty risk becoming dependent on external platforms, which can have strategic consequences during conflicts."3. Transformation of the Global Financial SystemIt was noted that traditional financial models face mounting challenges, including rising public debt, widening inequality, and geopolitical fragmentation. Technologies such as blockchain, artificial intelligence, and digital platforms are creating alternative financial mechanisms, including decentralised finance."The traditional model of cross-border payments is under pressure. Decentralised systems and digital technologies are reshaping the financial system," he said.4. Demographic Shifts and ChallengesThe fourth megatrend concerns global population dynamics. Global fertility rates have fallen sharply, with some countries facing critical declines. By the end of the 21st century, the working-age population may shrink significantly, while the proportion of elderly people rises, placing pressure on pension systems and social services."Even in Africa, the ratio of elderly to working-age population will rise to 30%, and globally to 56%," Oreshkin explained. "Education demand will decrease, but healthcare and social service needs will grow. These interconnected trends will amplify each other."5. Human Capital Development in the Technological EraThe final megatrend focuses on human capital in a rapidly changing technological environment.Autonomous systems, digital platforms, and artificial intelligence are transforming education, work, and healthcare, while biotechnologies expand human capabilities."AI is both a challenge and an opportunity," Oreshkin said. "It allows personalized learning paths and supports teachers.Professions are changing: mid-level specialists will be in demand, and companies must retrain employees from junior positions. The social sphere will also evolve, ensuring active longevity in the new demographic era."Global PerspectiveThroughout the presentation, Oreshkin illustrated each trend with real-life examples from different continents: a manager from Asia, a farmer from Africa, and a homemaker from Eastern Europe. He highlighted that innovations in Africa could improve education and healthcare, Eastern Europe may see rising living standards and more efficient social systems, and Asia will require reskilling to meet changing labor demands."The world has entered a period of significant change in finance, demography, and other spheres. States, companies, and individuals must be prepared. Those who understand and adapt will shape the future," Oreshkin concluded.Open Dialogue on AirThis year, Open Dialogue introduced a podcast format — Open Dialogue on Air — featuring global experts discussing key trends in international development. Participants include award-winning Chinese sci-fi writer Chen Qiufan, Dr. Selina Neri of the Future Readiness Academy, Dr. Rais Hussin of EMIR Research (Malaysia), Prof. Wang Feng of UC Irvine, and global strategist Dr. Parag Khanna.First held in April 2025 at the Russia National Centre, the Open Dialogue brought together over 3,000 experts from dozens of countries. By presidential decree, it will now be held annually.Social LinksTelegram: https://t.me/gowithrussiaVK: https://vk.com/gowithrussiaOK: https://ok.ru/gowithrussiaDZen: https://dzen.ru/gowithrussiaContact for the mediaBrand: Russia National CentreContact: Media teamEmail: Pressa@russia.ru Website: https://russia.ruEssay Submission: https://dialog.russia.ru/en/ Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

SHENZHEN, Jan 30, 2026 - (ACN Newswire via SeaPRwire.com) - China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited, please refer to the announcement published by the Group on 22 April 2025 for details) received approval from the National Medical Products Administration of China (NMPA) on 30 January 2026 for the New Drug Application (NDA) of ruxolitinib phosphate cream (the “Product”) for the treatment of non-segmental vitiligo with facial involvement in children aged 12 years and older and adult patients. It is the first and only targeted drug approved in China for vitiligo, addressing a significant unmet clinical need.Ruxolitinib phosphate cream is the first and only drug approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for repigmentation in nonsegmental vitiligo[1,2]. Prior to receiving formal NDA approval, the Group benefited from the “Early and Pilot Implementation” policy granted to the Hainan Free Trade Port and Lecheng Pilot Zone (“Lecheng Pilot Zone”), the “Hong Kong and Macau Medicine and Equipment Connect” policy, and the clinically urgently needed imported drug policies of the Beijing and Tianjin Free Trade Zones, and had already initiated the pilot application of ruxolitinib phosphate cream. Currently, Boao Super Hospital has prescribed ruxolitinib phosphate cream to over 7,000 patients with non-segmental vitiligo, and more than twenty hospitals in Guangzhou, Shenzhen, Dongguan, Foshan, Zhongshan, Zhuhai, Jiangmen, Huizhou, Beijing and Tianjin have provided prescription services for the Product, demonstrating its clinical potential.The product has shown positive results in both overseas clinical studies and the real-world study in China: in two identical Phase III double-blind, randomized, placebo-controlled studies (TRuE-V1 and TRuE-V2) conducted overseas, the proportion of patients achieving the primary efficacy endpoint of at least 75% improvement in the Facial Vitiligo Area Score Index (F-VASI 75) after 24 weeks of treatment with ruxolitinib phosphate cream was 29.9% in both studies, significantly higher than the 7.5% and 12.9% in the placebo groups, respectively. Continued use up to 52 weeks showed sustained repigmentation[3]. In accordance with the relevant regulations of the Lecheng Pilot Zone's real-world data application pilot project, ruxolitinib phosphate cream underwent real-world study in China, demonstrating positive efficacy consistent with the results of overseas pivotal clinical studies. All secondary efficacy endpoints in both domestic and overseas clinical studies showed a benefit trend consistent with the primary efficacy endpoint, and the treatment effect for vitiligo continued to improve with prolonged treatment. Furthermore, according to safety monitoring data from the Lecheng Pilot Zone, no new safety event was identified, no adverse event (AE) leading to discontinuation or withdrawal of treatment occurred, and no study drug-related serious adverse event (SAE) occurred.This approval in vitiligo brings new hope for treatment to over 10 million vitiligo patients in China, addressing urgent clinical needs. At the same time, it will add to Dermavon’s product portfolio in the field of skin treatment, potentially synergizing with Dermavon’s commercialized innovative drug ILUMETRI (tildrakizumab injection), commercialized exclusive drug Hirudoid (mucopolysaccharide polysulfate cream), and a series of innovative drugs under development and dermatological skin care products, in terms of expert network and market resources, thereby potentially enhancing Dermavon's position in the field of skin health.Furthermore, the Phase III clinical trial in China of ruxolitinib phosphate cream for the treatment of mild to moderate atopic dermatitis (AD) has achieved positive results. Currently, the Group is actively advancing the NDA for ruxolitinib phosphate cream for the treatment of AD in China, which, if approved, will provide a new treatment option for a broader patient population with AD in China.About VitiligoVitiligo is a chronic autoimmune disease characterized by depigmentation of the skin, which results from the loss of pigment-producing cells known as melanocytes. It is estimated that there are approximately 10.3 million vitiligo patients in China and non-segmental vitiligo patients account for approximately 8.2 million[4]. Existing therapies, such as topical corticosteroids (TCS) and topical calcineurin inhibitors (TCIs), have clinical limitations, with adverse reactions or limited efficacy with long-term use. The NDA approval of ruxolitinib phosphate cream successfully fills the gap in targeted drug treatment for vitiligo and is of great landmark significance.More About Ruxolitinib Phosphate CreamRuxolitinib phosphate cream (Opzelura®), a novel cream formulation of the selective JAK1/JAK2 inhibitor ruxolitinib developed by Incyte, is approved for the topical treatment of nonsegmental vitiligo in adult and patients aged 12 years and older, and for the short-term and non-continuous chronic treatment of mild to moderate AD in patients aged 2 years and older without immunodeficiency in the U.S. In Europe, ruxolitinib phosphate cream is approved for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age.The Group, through a subsidiary of Dermavon entered into a Collaboration and License Agreement with Incyte for ruxolitinib phosphate cream on 2 December 2022, obtaining an exclusive license to develop, register and commercialize the Product in Mainland China, Hong Kong Special Administrative Region, Macau Special Administrative Region, Taiwan Region and eleven Southeast Asian countries (the “Territory”) and a non-exclusive license to manufacture the Product in the Territory. The subsidiary of Dermavon has sublicensed the relevant rights for the Product outside Mainland China to the Group (excluding Dermavon and its subsidiary).Incyte has worldwide rights for the development and commercialization of ruxolitinib phosphate cream, marketed in the United States and Europe as Opzelura®. Opzelura® and the Opzelura® logo are registered trademarks of Incyte.About CMSCMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardio-cerebrovascular/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group.Reference:1. The U.S. FDA approval information can be found on the Incyte official website, as follows:https://investor.incyte.com/news-releases/news-release-details/incyte-announces-us-fda-approval-opzeluratm-ruxolitinib-cream2. The EMA approval information can be found on the Incyte official website, as follows:https://investor.incyte.com/news-releases/news-release-details/incyte-announces-european-commission-approval-opzelurar3. The clinical studies information can be found on the Opzelura® official website, as follows:https://www.opzelura.com/opzelura-prescribing-information4. China Insights Consultancy’s industrial reportCMS Disclaimer and Forward-Looking StatementsThis press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/ Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, January 30, 2026 - (ACN Newswire via SeaPRwire.com) – As China’s first batch of Level 3 (L3) conditionally autonomous driving vehicles receives official market access, advanced smart driving is poised for its inaugural year of commercial explosion. At this pivotal juncture, Cheche Group Inc. (CCG) ("Cheche" or the "Company"), a leading global InsurTech platform, announced the signing of a strategic cooperation agreement with Volkswagen (Anhui) Digital Sales and Services Co., Ltd. (hereinafter "DSSO") and Beijing Cardif Airstar Property & Casualty Insurance Co., Ltd. (hereinafter "Cardif Airstar Insurance").This tripartite collaboration is more than just a deep dive into high-quality growth for New Energy Vehicle (NEV) insurance; it represents a core transition from "digitization" to "intelligence." The partnership establishes three strategic directions for synergy. First, it focuses on the transformation of product formats by leveraging Cheche’s SaaS platform to co-create an integrated "Insurance + Value-Added Services" package, enabling the efficient, one-stop fulfillment of high-value services. Second, it upgrades pricing capabilities by deeply integrating compliant driving data with dynamic vehicle information, utilizing AI-driven risk profiling to achieve differentiated precision pricing while addressing the complex challenge of liability determination in human-machine co-driving scenarios. Finally, it expands the ecosystem dimension by embedding insurance services throughout the vehicle sales and after-sales process, extending the business from a single policy to a full-lifecycle service ecosystem that encompasses renewal management and mobility protection.01. Smart Driving Insurance: Securing "Pricing Authority" in the L3 Mass Production EraTraditional auto insurance has long struggled with "human-machine co-driving" scenarios due to a lack of real-time dynamic data for liability determination and precise risk identification. Having served leading automakers such as Tesla, Li Auto, and Xiaomi, Cheche provides VW Anhui Digital with an embedded SaaS system centered on data attribution and dynamic pricing.Through this SaaS infrastructure, vehicle driving data is seamlessly synchronized with BNP Paribas Star’s actuarial models. This AI-driven joint risk profiling not only resolves the technical difficulties of liability judgment in smart driving scenarios but also delivers a "low-premium rewards for safe drivers," serving as a vital solution to the profitability challenges currently facing the NEV insurance industry.02. Ecosystem Breakthrough: Leveraging the "Xiaomi + Volkswagen DSSO" New Quality Productive ForcesInvestors are closely watching the cross-sector dynamics underpinning this collaboration. Cardif Airstar Insurance was co-founded by Xiaomi Group, Volkswagen Financial Services, and Cardif Airstar Insurance, combining the strengths of an internet giant, a global financial powerhouse, and a leading smart automaker.As the hub connecting these forces with Volkswagen’s Hefei Intelligent Electric Vehicle Center, Cheche is penetrating the world’s top smart driving supply chains. This is not merely system integration; it marks Cheche’s evolution into a digital operator within the "Vehicle-Battery-Charging-Insurance" integrated landscape. Amid policy tailwinds such as "New Quality Productive Forces," Cheche’s closed-loop ecosystem is becoming a definitive growth pole for insurance and tech capital.03. Scenario Transformation: From Transactional Policies to Full-Lifecycle OperationsIn 2026, as the automotive market shifts from a competition over hardware parameters to a competition over user experience, Cheche is helping DSSO deeply couple insurance services with the car-buying and after-sales journey. The integrated service package transforms insurance from a low-frequency tool into a high-frequency touchpoint for user engagement.Christian Koenig, After-sales Director of DSSO, noted that Cheche’s technical foundation allowed the partnership to advance rapidly from a high starting point. This "plug-and-play" empowerment capability, proven by mainstream automakers, has become a technical moat for Cheche in the capital markets.04. Conclusion: The Final Piece of the Trillion-Dollar Blue OceanThe year 2026 marks the point where NEV insurance evolves from scale expansion to intelligent upgrades. Cheche will continue to advance its AI pricing engine, driving the leap from digital to intelligent services.According to data released by the Ministry of Public Security on January 26, China’s NEV ownership reached 43.97 million units by the end of 2025, accounting for 12.01% of the total vehicle population—a growth rate exceeding 40% year-over-year. In this environment, those who define the insurance standards for the smart driving era will control the entry point to future mobility. With its high barriers to entry via OEM partnerships and forward-looking AI layouts, Cheche is racing toward becoming a leader in the trillion-dollar NEV insurance market. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, January 30, 2026 - (ACN Newswire via SeaPRwire.com) – 27 January 2026, Nissin Foods (Hong Kong) Charity Fund (“Charity Fund”) announced its continued support for elite athletes from The Education University of Hong Kong (“EdUHK”) for the fourth consecutive year. The Presentation Ceremony for the Nissin Foods Scholarship for Elite Athletes 2025/2026 was held to honour seven outstanding athletes who not only demonstrate excellence in their respective sports but also aspire to become future educators. The scholarship will cover their full tuition fees throughout their entire study period, enabling them to pursue their academic and athletic goals without financial concerns.Established in 2022 by the Nissin Foods (Hong Kong) Charity Fund, the scholarship is designed to encourage elite athletes enrolled in the Bachelor of Health Education (Honours), Bachelor of Science (Honours) in Sports Science and Coaching, or the Postgraduate Diploma in Education programme at EdUHK. The initiative aims to support their dual career development, empowering them to become qualified health educators while continuing to strive for excellence in their athletic performance.The seven awardees for the 2025/2026 academic year include new and renewing recipients. The four new awardees are: Mr. MOK Pak Fan (triathlon), Mr. WONG Pak Yiu (triathlon), Miss HO Kin Yiu (volleyball), and Miss YAN Nuo (shuttlecock). In addition to welcoming new scholars, the Charity Fund also made the scholarship renewable to support the elite athletes throughout their study period. The three recipients of the renewed scholarship are: Mr. CHOI Kwan Lok (cycling, retired), Mr. CHEN Pak Hong (rowing), and Mr. Joseph LAU (cycling).Mr. Kiyotaka ANDO, Chairman of Nissin Foods (Hong Kong) Charity Fund, said, “Having been deeply rooted in Hong Kong for over four decades, Nissin Foods is steadfast in its mission to give back to the community. This scholarship is a direct reflection of our founder Mr. Momofuku Ando’s philosophy that ‘Eating and sports are the two axles of health.’ By supporting these talented athletes at EdUHK for the fourth year, we are not just providing financial support, we are investing in future leaders who will champion health and wellness in our society. We are proud to empower them on their dual career path, confident that they will inspire the next generation as both accomplished athletes and dedicated educators.”Expressing his profound gratitude for the long-standing partnership, Professor Chetwyn CHAN, Vice President (Research and Development) of EdUHK, said, “EdUHK is dedicated to promoting sustainable dual-career pathways for high-performance athletes. The generous Nissin Foods Scholarship for Elite Athletes allows us to support both active and retired athletes in advancing their educational pursuits, while also recognising their exceptional sporting accomplishments. I would like to extend my heartfelt congratulations to all the scholarship recipients, who demonstrated great passion, determination, and a sense of mission, and sincerely thank the Nissin Foods (Hong Kong) Charity Fund, and Mr Ando for the tremendous support and confidence in health education and the development of elite athletes.”Accomplished volleyball player Miss HO Kin Yiu, recipient of the scholarship from the Postgraduate Diploma in Education, majoring in Chinese and Physical Education, shared her heartfelt appreciation to the Charity Fund, “The support of the scholarship empowers us, as elite athlete-students, to chase our aspirations and make a meaningful influence on society. We are confident that we can help create a brighter future through the spirit of sports and education.”PhotoMr. Kiyotaka ANDO, Chairman of Nissin Foods (Hong Kong) Charity Fund (middle right), and Professor Chetwyn CHAN, Vice President (Research and Development) of EdUHK (middle left), attended the Presentation Ceremony for Nissin Foods Scholarship for Elite Athletes 2025/2026 on 27 January 2026. Five scholarship recipients attended the ceremony, including four new awardees for the 2025/2026 academic year, namely: (from left to right) Mr. MOK Pak Fan, Mr. WONG Pak Yiu, Miss HO Kin Yiu, and Miss YAN Nuo, as well as the renewed awardee - Mr. CHOI Kwan Lok. Awardees of the Nissin Foods Scholarship for Elite Athletes 2025/2026 are achieving great success in their individual disciplines. From top left: Mr. WONG Pak Yiu (triathlon), Miss HO Kin Yiu (volleyball), Mr. MOK Pak Fan (triathlon), Miss YAN Nuo (shuttlecock), Mr. CHOI Kwan Lok (cycling, retired), Mr. CHEN Pak Hong (rowing), and Mr. Joseph LAU (cycling).About Nissin Foods (Hong Kong) Charity FundThe Nissin Foods (Hong Kong) Charity Fund (“Charity Fund”) was set up in September 2020 by way of a trust deed by Nissin Foods Company Limited (Stock code: 1475). The objectives of the Charity Fund are: a) to advance education, teaching, learning, arts, science and academic research; b) to make provision for people in need; and c) to carry out works of a charitable nature that are beneficial to the Hong Kong community. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年1月30日 - (亞太商訊 via SeaPRwire.com) - 2026年1月27日，日清食品（香港）慈善基金（「慈善基金」）宣布連續第四年支持香港教育大學（「教大」）精英運動員，並舉行2025/2026 學年日清食品精英運動員獎學金頒獎典禮，以表彰在各自運動領域中表現卓越、並立志成為未來教育工作者的七位精英運動員。該獎學金將支付整個修業期的全額學費，確保他們能夠專注追求學業及運動目標，無須擔心財務負擔。該獎學金於2022年由日清食品（香港）慈善基金設立，以鼓勵於教大修讀健康教育（榮譽）學士課程、運動科學及教練（榮譽）理學士及學位教師教育文憑課程的精英運動員。此舉措旨在支持他們的雙軌事業發展，賦予他們能力成為合資格的健康教育工作者，同時在運動表現上繼續追求卓越。2025/2026 學年的七名得獎者包括新晉及續期獎學金的精英運動員。四名新得獎的精英運動員分別是：鐵人三項代表莫柏勛先生和黃栢堯先生、排球代表何健瑤小姐以及香港足毽隊代表閻諾小姐。除了新的獎學金得主，慈善基金亦將該獎學金設為可續期形式，為精英運動員提供整個學習期間的資助支持。獲得續期獎學金的三名精英運動員包括：前香港單車隊代表蔡鈞樂先生、賽艇代表陳柏匡先生及香港單車隊代表劉睿哲先生。日清食品（香港）慈善基金主席安藤清隆先生表示：「日清食品在香港扎根逾 40 年，我們堅定不移地履行回饋社會的使命。獎學金直接體現了我們的創辦人安藤百福先生『飲食和運動是健康的兩大軸心』的理念。透過連續第四年支持教大的傑出運動員，我們不僅提供經濟資助，更是在投資未來的領袖，他們將在我們的社會中倡導健康與福祉。我們很自豪能在他們的雙軌發展道路上賦予他們力量，並深信他們將以傑出運動員和敬業教育工作者的雙重身份，啟發下一代。」香港教育大學副校長（研究與發展）陳智軒教授對長期的合作夥伴關係表達深切感謝。他表示：「教大致力推動精英運動員發展可持續的雙軌事業路徑。日清食品精英運動員獎學金的慷慨支持令我們能夠讓現役及退役運動員繼續進修，同時認可了他們卓越的運動成就。我衷心祝賀所有獎學金得主，他們展現了極大的熱情、決心和使命感，並誠摯感謝日清食品（香港）慈善基金及安藤先生對健康教育和精英運動員發展的巨大支持及信心。」主修中文及體育的學位教師教育深造文憑獎學金得獎人及傑出排球運動員何健瑤小姐對慈善基金表達衷心謝意。她說：「獎學金的支持賦予我們精英運動員學生力量，去追逐我們的抱負，並為社會帶來有意義的影響。我們深信，我們能透過體育和教育的精神，創造更美好的未來。」圖片說明日清食品（香港）慈善基金主席安藤清隆先生（中間右）及香港教育大學副校長（研究與發展）陳智軒教授（中間左）於2026年1月27日出席2025/2026學年日清食品精英運動員獎學金頒獎典禮。五名獎學金得主參與典禮，包括四名新得獎的精英運動員學生（從左至右）莫柏勛先生、黃栢堯先生、何健瑤小姐及閻諾小姐，以及獲得續期獎學金的精英運動員學生蔡鈞樂先生。 2025/2026年度日清食品精英運動員獎學金得獎人在各自領域均表現出色。左上起：鐵人三項代表黃栢堯先生、排球代表何健瑤小姐、鐵人三項代表莫柏勛先生、香港足毽隊代表閻諾小姐、前香港單車隊代表蔡鈞樂先生、賽艇代表陳柏匡先生及香港單車隊代表劉睿哲先生。關於日清食品（香港）慈善基金日清食品（香港）慈善基金（「慈善基金」）於2020年 9月由日清食品有限公司（股份編號： 1475）以信託契約的形式成立。慈善基金致力推動教育、教學、學習、藝術、科學和學術研究、援助有需要人士及進行惠及香港社區的慈善工作。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年1月30日 - (亚太商讯 via SeaPRwire.com) - 日清食品（香港）慈善基金（「慈善基金」）宣布连续第四年支持香港教育大学（「教大」）精英运动员，并举行2025/2026 学年日清食品精英运动员奖学金颁奖典礼，以表彰在各自运动领域中表现卓越、并立志成为未来教育工作者的七位精英运动员。该奖学金将支付整个修业期的全额学费，确保他们能够专注追求学业及运动目标，无须担心财务负担。该奖学金于2022年由日清食品（香港）慈善基金设立，以鼓励于教大修读健康教育（荣誉）学士课程、运动科学及教练（荣誉）理学士及学位教师教育文凭课程的精英运动员。此举措旨在支持他们的双轨事业发展，赋予他们能力成为合资格的健康教育工作者，同时在运动表现上继续追求卓越。2025/2026 学年的七名得奖者包括新晋及续期奖学金的精英运动员。四名新得奖的精英运动员分别是：铁人三项代表莫柏勋先生和黄柏尧先生、排球代表何健瑶小姐以及香港足毽队代表阎诺小姐。除了新的奖学金得主，慈善基金亦将该奖学金设为可续期形式，为精英运动员提供整个学习期间的资助支持。获得续期奖学金的三名精英运动员包括：前香港单车队代表蔡钧乐先生、赛艇代表陈柏匡先生及香港单车队代表刘睿哲先生。日清食品（香港）慈善基金主席安藤清隆先生表示：「日清食品在香港扎根逾 40 年，我们坚定不移地履行回馈社会的使命。奖学金直接体现了我们的创办人安藤百福先生『饮食和运动是健康的两大轴心』的理念。透过连续第四年支持教大的杰出运动员，我们不仅提供经济资助，更是在投资未来的领袖，他们将在我们的社会中倡导健康与福祉。我们很自豪能在他们的双轨发展道路上赋予他们力量，并深信他们将以杰出运动员和敬业教育工作者的双重身份，启发下一代。」香港教育大学副校长（研究与发展）陈智轩教授对长期的合作伙伴关系表达深切感谢。他表示：「教大致力推动精英运动员发展可持续的双轨事业路径。日清食品精英运动员奖学金的慷慨支持令我们能够让现役及退役运动员继续进修，同时认可了他们卓越的运动成就。我衷心祝贺所有奖学金得主，他们展现了极大的热情、决心和使命感，并诚挚感谢日清食品（香港）慈善基金及安藤先生对健康教育和精英运动员发展的巨大支持及信心。」主修中文及体育的学位教师教育深造文凭奖学金得奖人及杰出排球运动员何健瑶小姐对慈善基金表达衷心谢意。她说：「奖学金的支持赋予我们精英运动员学生力量，去追逐我们的抱负，并为社会带来有意义的影响。我们深信，我们能透过体育和教育的精神，创造更美好的未来。」图片说明日清食品（香港）慈善基金主席安藤清隆先生（中间右）及香港教育大学副校长（研究与发展）陈智轩教授（中间左）于2026年1月27日出席2025/2026学年日清食品精英运动员奖学金颁奖典礼。五名奖学金得主参与典礼，包括四名新得奖的精英运动员学生（从左至右）莫柏勋先生、黄柏尧先生、何健瑶小姐及阎诺小姐，以及获得续期奖学金的精英运动员学生蔡钧乐先生。 2025/2026年度日清食品精英运动员奖学金得奖人在各自领域均表现出色。左上起：铁人三项代表黄柏尧先生、排球代表何健瑶小姐、铁人三项代表莫柏勋先生、香港足毽队代表阎诺小姐、前香港单车队代表蔡钧乐先生、赛艇代表陈柏匡先生及香港单车队代表刘睿哲先生。关于日清食品（香港）慈善基金日清食品（香港）慈善基金（「慈善基金」）于2020年 9月由日清食品有限公司（股份编号： 1475）以信托契约的形式成立。慈善基金致力推动教育、教学、学习、艺术、科学和学术研究、援助有需要人士及进行惠及香港社区的慈善工作。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com